Renaissance Technologies LLC cut its holdings in Davita Inc (NYSE:DVA) by 2.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 634,800 shares of the company’s stock after selling 17,400 shares during the quarter. Renaissance Technologies LLC owned approximately 0.38% of Davita worth $45,471,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Honkamp Krueger Financial Services Inc. purchased a new stake in shares of Davita during the third quarter valued at about $143,000. Atlas Capital Advisors LLC lifted its position in shares of Davita by 247.9% during the third quarter. Atlas Capital Advisors LLC now owns 2,592 shares of the company’s stock valued at $188,000 after buying an additional 1,847 shares during the last quarter. Green Square Capital LLC purchased a new stake in shares of Davita during the second quarter valued at about $208,000. Seven Eight Capital LP purchased a new stake in shares of Davita during the third quarter valued at about $219,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Davita during the third quarter valued at about $249,000. 85.68% of the stock is owned by institutional investors.
DVA opened at $58.02 on Friday. Davita Inc has a 52-week low of $56.89 and a 52-week high of $80.71. The company has a debt-to-equity ratio of 2.09, a quick ratio of 1.82 and a current ratio of 1.84. The stock has a market cap of $9.63 billion, a PE ratio of 16.21, a P/E/G ratio of 0.77 and a beta of 1.07.
Davita (NYSE:DVA) last posted its quarterly earnings data on Wednesday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.89 by ($0.33). Davita had a net margin of 5.39% and a return on equity of 13.87%. The company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.93 billion. During the same quarter last year, the company earned $0.81 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. On average, analysts anticipate that Davita Inc will post 3.56 earnings per share for the current fiscal year.
DVA has been the subject of several analyst reports. JPMorgan Chase & Co. raised shares of Davita from an “underweight” rating to a “neutral” rating in a research report on Thursday, September 13th. Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $81.00 price objective on the stock in a report on Monday, October 8th. ValuEngine upgraded shares of Davita from a “hold” rating to a “buy” rating in a report on Tuesday, October 9th. Raymond James downgraded shares of Davita from a “strong-buy” rating to a “market perform” rating in a report on Thursday, November 8th. Finally, Royal Bank of Canada upped their price objective on shares of Davita from $70.00 to $78.00 and gave the company a “sector perform” rating in a report on Thursday, November 8th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $78.18.
ILLEGAL ACTIVITY WARNING: “Renaissance Technologies LLC Lowers Position in Davita Inc (DVA)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/12/16/renaissance-technologies-llc-lowers-position-in-davita-inc-dva.html.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading: NASDAQ
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.